Is this the right target? Ask the whole record.
Human genetics, mechanism, tractability and the competitive field for any target, read from full text and returned with sources.
| Evidence | Finding | Source |
|---|---|---|
| Human genetics | A partial loss-of-function variant (P1104A) is associated with protection from several autoimmune diseases | Dendrou et al., Sci Transl Med, 2016 |
| Tractability | Selective inhibition through the pseudokinase (JH2) domain rather than the conserved ATP site | Wrobleski et al., J Med Chem, 2019 |
| Clinical precedent | Deucravacitinib approved by the FDA for plaque psoriasis in 2022 | FDA label, 2022 |
| Competition | About 30 active interventional trials | ClinicalTrials.gov |
Questions
The questions at this stage.
- What human genetic evidence links TYK2 to autoimmune disease?
- Which cell types express the target, and what happens on knockout?
- Is there a tractable binding site, and what chemical matter already exists?
- Who else is in the clinic on this target, and at what phase?
Related use cases
Also at this stage.
The narrower questions teams bring to this stage.
Target–disease association
Genetic and functional evidence linking a target to a disease, from Open Targets and the literature.
Biomarker discovery
Candidate biomarkers and the cohorts, assays and effect sizes behind them.
Indication expansion
Other diseases where the same target or mechanism has supporting evidence.
Disease pathophysiology
Mechanism and pathway literature for the disease, with conflicting findings flagged.
Target safety
Knockout phenotypes, human loss-of-function carriers and on-target toxicity reports.
Applications
What teams build.
Target dossier generators
One cited brief per target, rebuilt when new evidence posts.
Target ranking agents
Score a longlist on genetics, safety and competition, each score with its sources.
Hypothesis tools
Surface mechanism links buried in methods and results sections.
Try it on your target
Name a target. See what the record says.
Get the genetics, tractability and competitive field back as a cited dossier your team can check line by line.